A Systematic Review and Meta-Analysis of Metabolic Syndrome
                    Prevalence in Chinese Inpatients with Bipolar Disorder

Hejian Tao; Dong Shen; Yong Zhou; Fengli Sun; Guorong Li; Weidong Jin

doi:10.1055/a-1882-8423

Hormone and Metabolic Research, Inhaltsverzeichnis

Horm Metab Res 2022; 54(09): 587-592
DOI: 10.1055/a-1882-8423

Original Article: Endocrine Care

A Systematic Review and Meta-Analysis of Metabolic Syndrome Prevalence in Chinese Inpatients with Bipolar Disorder

Authors

Hejian Tao

¹Psychiatry Department, Zhejiang Chinese Medical University, Hangzhou, China
Dong Shen

²Psychiatry Department, Jiaxing Kangci Hospital, Jiaxing, China
Yong Zhou

²Psychiatry Department, Jiaxing Kangci Hospital, Jiaxing, China
Fengli Sun

³Psychiatry Department, Zhejiang Province Mental Health Center, Hangzhou, China
Guorong Li

²Psychiatry Department, Jiaxing Kangci Hospital, Jiaxing, China
Weidong Jin

¹Psychiatry Department, Zhejiang Chinese Medical University, Hangzhou, China

Abstract

The aim of the work was to study the prevalence of metabolic syndrome in Chinese patients with bipolar disorder. We searched Chinese literature related to the study in prevalence of metabolic syndrome in bipolar disorder in Chinese language, among which results such as comments, letters, reviews and case reports were excluded. The prevalence of metabolic syndrome in bipolar disorder was researched and discussed. A total of 1562 subjects were included in 11 studies. The prevalence of MetS in bipolar disorder was 33% (95% CI=0.29–0.37), which was higher significantly than normal control (10.82%), but similar to schizophrenia (31.59%). The 41.41% prevalence of MetS in male patients was higher significantly than that in females (26.83%).The prevalence of MetS in BD treated by AAP was 47.54%, by MS was 19.19%, by MS+AAP was 40%.The prevalence of MetS in BD treated by carbamazepine was 28.21%, by lithium was 30%, by valproate was 21.71%, by clozepine was 51.43%, by olanzapine was 39.84%, by quetiapine was 39.44%, and by risperidone was 35%. The prevalence of MetS in bipolar disorder was 33% (95% CI=0.29–0.37), which was higher significantly than normal control (10.82%), but similar to schizophrenia (31.59%). AAP and MS were the main one risks of MetS in BD.

Key words

bipolar disorder - metabolic syndrome - meta-analysis - systematic review

Volltext

Referenzen

References
1 Saklayen MG. The global epidemic of the metabolic syndrome. Curr Hypertens Rep 2018; 20: 12
2 Sherling DH, Perumareddi P, Hennekens CH. Metabolic syndrome. J Cardiovasc Pharmacol Ther 2017; 22: 365-367
3 Aguilar M, Bhuket T, Torres S. et al. Prevalence of the metabolic syndrome in the United States, 2003-2012. JAMA 2015; 313: 1973 1974
4 Li R, Li WH, Lun ZJ. et al. Prevalence of metabolic syndrome in mainland China: a meta-analysis of published studies. BMC Public Health 2016; 16: 296
5 Freund N, Juckel G. Bipolar disorder: its etiology and how to model in rodents. Methods Mol Biol 2019; 2011: 61-77
6 Brietzke E, Kapczinski F, Grassi-Oliveira R. et al. Insulin dysfunction and allostatic load in bipolar disorder. Expert Rev Neurother 2011; 11: 1017-1028
7 de Almeida KM, Moreira CLRL, Lafer B. Bipolar disorder: what should psychiatrists know?. CNS Neurosci Ther 2012; 18: 160-166
8 McElroy SL, Keck PE. Metabolic syndrome in bipolar disorder: a review with a focus on bipolar depression. J Clin Psychiatry 2014; 75: 46-61
9 Li BL, Jin WD. Risks of metabolic syndrome in bipolar disorder. Clin J Psychosom Dis 2012; 25: 470-472
10 Zhu J, Xiao WB, Dai XL. Correlation between CRP expression and MS in patients with schizophrenia and bipolar disorder. J Clin Psychosom Dis 2020; 26: 21-24
11 Xiang H, Mao RZ, Zhao GQ. et al. Cormorbid metabolic syndrome and its risk factors of patients with bipolar disorder. Chin J Psychiatry 2017; 50: 107-112
12 Czepielewski L, Filho LD. Brietzke et al. Bipolar disorder and metabolic syndrome: a systematic review. J Psychiatry 2013; 35: 88-93
13 Dalkner N, Bengesser SA, Birner A. et al. Metabolic syndrome impairs executive function in bipolar disorder. Front Neurosci 2021; 15: 717824
14 Kocakaya IH, Songur E, Batmaz S. et al. Impact of metabolic syndrome and clinical features on functioning in patients with bipolar disorder: a cross-sectional study. Braz J Psychiatry 2020; 42: 373-381
15 Stroup DF, Berlin JA, Morton SC. et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. JAMA 2000; 283: 2008-2012
16 Celiac disease. Rockville: agency for healthcare research and quality (US); 2004. https://www.ncbi.nlm.nih.gov/books/NBK35149/
17 Zhang XM, Chen JX, Zhang LC. et al. Investigation of metabolic syndrome in inpatients with bipolar disorder. J Clin Psychiatry 2015; 25: 248-250
18 Chen HH, Zhu YP, Lai KX. et al. Analysis of risk factors of metabolic syndrome in inpatients with bipolar disorder. Guangdong Med J 2018; 39: 3373-3376
19 Huan GH, Liu HR, Zhang JP. et al. The prevalence of metabolic syndrome and lifestyle in bipolar disorder patients. Chin Behav Med. Brain Sci 2010; 19: 601-603
20 Zhou DM. Comparison of prevalence of metabolic syndrome between patients with bipolar disorder and schizophrenia. Med J Chin People Health 2011; 23: 1496-1497
21 Fang YY, Zhou W, Sun N. et al. Effects of metabolic syndrome on clinical prognosis of patients with bipolar disorder. Med J Chin People Health 2017; 29: 4-18
22 Zhang DC, Hu XL. Prevalence investigation and analysis of risk factors related cormorbid metabolic syndrome in patients with bipolar disorder. Fam Med 2020; 9: 387-388
23 Zhang BT, Qian J. Atypical antipsychotic drugs for patients with bipolar disorder and metabolism research. China Health Indust 2013; 3: 16-18
24 Liu L, Qin XX, Xie SF. et al. Metabolic syndrome in bipolar patients with atypical antipsychotics. Chin Gen Pract 2007; 10: 1243-1244
25 Li JH, Zhong H, Wang SK. et al. Risk factors for metabolic syndrome in patients with bipolar disorder. Shanghai Arch Psychiatry 2009; 21: 209-212
26 Grover S, Mehra A, Chakravarty R. et al. Change in prevalence of metabolic syndrome in patients with bipolar disorder. Asian J Psychiatry 2020; 47: 101876
27 Li C, Birmaher B, Rooks B. et al. High prevalence of metabolic syndrome among adolescents and young adults with bipolar disorder. J Clin Psychiatry 2019; 80: 18m12422
28 Mohite S, Wu H, Sharma S. et al. Higher prevalence of metabolic syndrome in child-adolescent patients with bipolar disorder. Clin Psychopharmacol Neurosci 2020; 18: 279-288
29 Nayerifard R, Bureng MA, Zahiroddin A. et al. Comparison of metabolic syndrome prevalence in patients with schizophrenia and bipolar I disorder. Diabetes Metab Syndr 2017; 11 (Suppl 1): S411-S416
30 de Jong M, Belleflamme J, Dale C. et al. Metabolic syndrome in Dutch patients with bipolar disorder: a cross-sectional study. Prim Care Companion CNS Disord 2018; 20: 18m02366
31 Vancampfort D, Vansteelandt K, Correll UC. et al. Metabolic syndrome and metabolic abnormalities in bipolar disorder: a meta-analysis of prevalence rates and moderators. Am J Psychiatry 2013; 170: 265-274
32 Mazereel V, Detraux J, Vancampfort D. et al. Impact of psychotropic medication effects on obesity and the metabolic syndrome in people with serious mental illness. Front Endocrinol (Lausanne) 2020; 11: 573479
33 Barton BB, Zagler A, Engl K. et al. Prevalence of obesity, metabolic syndrome, diabetes and risk of cardiovascular disease in a psychiatric inpatient sample: results of the Metabolism in psychiatry (MiP) study. Eur Arch Psychiatry Clin Neurosci 2020; 270: 597-609
34 Dolab N, Kamkar MZ, Amiriani T. et al. The association between leptin and adiponectin, and metabolic syndrome components and serum levels of lipid peroxidation in bipolar disorder patients treated with lithium and valproic acid. Heliyon 2020; 6: e04553
35 Cerit C, Vural MM, Gelmez SÜB. et al. Metabolic syndrome with different antipsychotics: a multicentre cross-sectional study. Psychopharmacol Bull 2010; 43: 22-36